Business
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
- Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles - SOUTH SAN FRANCISCO,
About this update from Veracyte, Inc.
[{"type":"text","content":"\n- Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles -\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1. Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from thyroid nodules analyzed with the Afirma GSC.\n\n\n“As we enter a new era in the personalized diagnosis and management of thyroid nodules and cancer, it is more important than ever to advance the science around this cancer so we can ultimately characterize each patient’s individual molecular profile,” said Joshua Klopper, MD, Veracyte’s medical director for Endocrinology. “The abstracts to be presented by our clinical research colleagues at the ATA meeting show that the Afirma GSC platform can be used to glean new insights about thyroid nodules and thyroid cancer preoperatively. We believe that Afirma-based whole-transcriptome analysis will help drive cancer research and unlock findings that may ultimately be used in clinical care.”\n\n\nThe following late-breaking posters will be presented at the 2023 ATA Annual Meeting (all times ET):\n\n\nTitle: Leveraging RNA Sequencing for Pre-Operative Immunophenotyping of BRAFV600E+ Thyroid Nodules\nPresenter: Jarod Olay, M.S., UCLA David Geffen School of Medicine\nPoster #: 502\nDate/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m.\nTitle: Molecular Assessment of Isthmus Thyroid Carcinomas\n\n\nPresenter: Sina Jasim, M.D., Washington University in St. Louis\nPoster #: 501\nDate/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m.\nTitle: Sodium Iodide Symporter (NIS) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules\n\n\nPresenter: Prasana Santhanam, M.B.B.S., M.D., The Johns Hopkins University School of Medicine\nPoster #: 515\nDate/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m.\n\n\nThese abstracts will later be published as an online supplement to Thyroid, the official jo...